Patents for A61P 35 - Antineoplastic agents (221,099)
07/2004
07/22/2004WO2004060899A1 Phospholipid derivatives and process for the production there
07/22/2004WO2004060890A1 2-oxopyridin-3-yl thia (di) azole derivates for use in the treatment of cell proliferation and apoptosis related diseases
07/22/2004WO2004060881A1 1,3-benzothiazinone derivatives, process for producing the same and use thereof
07/22/2004WO2004060488A1 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
07/22/2004WO2004060398A1 Connexin 26 inhibitors and cancer metastasis inhibitors
07/22/2004WO2004060390A2 Use of a specific inhibitor of the 5ht2b receptor for the treatment of cancer
07/22/2004WO2004060376A1 The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
07/22/2004WO2004060304A2 Novel compositions and methods in cancer
07/22/2004WO2004060270A2 Compositions and methods for the diagnosis and treatment of tumor
07/22/2004WO2004060264A2 Metastin derivatives and their use
07/22/2004WO2004060262A2 Modulators of notch signalling for use in immunotherpapy
07/22/2004WO2004060261A2 Novel factor viia inhibiting compounds
07/22/2004WO2004060055A1 Wt1 transgenic animal
07/22/2004WO2004039359A3 Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders
07/22/2004WO2004037235A3 Method and composition for preventing and treating solid tumors
07/22/2004WO2004037187A8 Metal-containing materials, compositions and methods
07/22/2004WO2004035034A3 Clofarabine and taxane chemotherapy combination
07/22/2004WO2004035033A3 Clofarabine and camptothecin chemotherapy combination
07/22/2004WO2004024884A3 Syts as modifiers of the p21 pathway and methods of use
07/22/2004WO2004024735A3 A new process for the preparation of epothilone derivatives, new epothilone derivatives as well as new intermediate products for the process and the methods of preparing same
07/22/2004WO2004024086A3 Compounds, compositions and methods
07/22/2004WO2004021977A3 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
07/22/2004WO2004006835A3 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
07/22/2004WO2004005529A3 GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF
07/22/2004WO2003103743A3 Medical device for intra-lumenal delivery of pharmaceutical agents
07/22/2004WO2003103583A8 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
07/22/2004WO2003101919A3 Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same
07/22/2004WO2003087304A3 Tri-substituted heteroaryls and methods of making and using the same
07/22/2004WO2003070675A3 Substituted 10-aryl-11h-benzo[b]fluorenes and 7-aryl-5,6-dihydro-benzo[a]anthracenes for selective effects on estrogen receptors
07/22/2004WO2003059293A3 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
07/22/2004WO2003059148A3 Gene expression profiles in stomach cancer
07/22/2004WO2003053215A3 Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
07/22/2004WO2003014299A3 SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
07/22/2004WO2003014296A3 A group of novel anti-cancer compounds with specific structure
07/22/2004WO2003006002A9 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
07/22/2004WO2002101076A3 Methods for targeted expression of therapeutic nucleic acid
07/22/2004WO2002099048A3 LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
07/22/2004WO2002088090A3 Pyrazole derived kinase inhibitors
07/22/2004US20040143131 in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates
07/22/2004US20040143117 serine/threonine kinase inhibitors; 2,3-diphenylquinoxalines in which at least one of the phenyls is substituted with an amine group, particularly 2-[4-(2-aminoprop-2-yl)phenyl]-3-phenylquinoxaline; treating cancer
07/22/2004US20040143115 e.g., 1-[2-Benzoxazol-2-ylaminomethyl)-piperidin-1-yl]-1-(2-methyl-5phenyl-thiazol4-yl)-methanone; used to treat disorders where an antagonist of a human orexin receptor is required
07/22/2004US20040143101 Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
07/22/2004US20040143014 Therapeutic use of alpha-2-delta ligands
07/22/2004US20040142999 Novel compounds and compositions as cathepsin inhibitors
07/22/2004US20040142990 Concentrating epothilone in culture; complexing; antiproliferative agents
07/22/2004US20040142987 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
07/22/2004US20040142982 Urea derivatives as integrin alpha 4 antagonists
07/22/2004US20040142979 Cardiovascular disorders; respiratory system disorders; kidneys; liver diosrders; central nervous system diosrders; osteoarthritis; antiarthritic agents; antitumor agents; multiple sclerosis
07/22/2004US20040142976 Modulation cytokine sensitive diseases, cellular adhesion molecules; Aids therapy; antihistamines; antiarthritic agents; bone disorders; malaria; cachexia; Crohn's disease
07/22/2004US20040142963 Cardiovascular disorders
07/22/2004US20040142960 Yohimbine as immunobiologically active agent
07/22/2004US20040142953 Inhibitors of histone deacetylase
07/22/2004US20040142952 Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension
07/22/2004US20040142947 Pyrrolopyrimidines
07/22/2004US20040142934 treatment of rheumatoid arthritis and/or pain; INHIBIT activity of VEGF receptor tyrosine kinase and VEGF-dependent cell proliferation
07/22/2004US20040142932 treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase activity
07/22/2004US20040142927 Inhibitors of p38
07/22/2004US20040142920 acute or chronic transplant rejection or inflammatory or autoimmune diseases
07/22/2004US20040142919 Benzazepinone alpha vintegrin receptor antagonists
07/22/2004US20040142909 Colchinol derivatives as angiogenesis inhibitors
07/22/2004US20040142900 polypeptide with the transport function of herpesviral VP22 protein and which can regulate cell cycle progression, e.g. proteins which can induce apoptosis, or proteins which can arrest cells from the cell cycle to arrest cell proliferation
07/22/2004US20040142885 host cell; gene therapy
07/22/2004US20040142882 Use of glycyrrhizin and its derivatives as RANTES inducers
07/22/2004US20040142877 Ligands of the $g(a)v$g(b)6 integrin
07/22/2004US20040142875 "metastin" is the ligand to a G-protein-coupled orphan receptor known as OT7T175 or AXOR12; prodrug; treating cancer, hydatid mole, invasive mole, miscarriage, fetal hypoplasia, sugar dysbolism, lipid dysbolism or labor induction in a mammal
07/22/2004US20040142867 Stabilized proteinic preparation
07/22/2004US20040142851 by inducing the apoptosis according to a inhibition mechanism of the enzyme activities of proteasome
07/22/2004US20040142432 Preparing single chain antibodies comprised of camelid subunits for treating and preventing inflammation, allergies, cancer, infections, transplant rejection, autoimmune and muscular disorders
07/22/2004US20040142431 Nucleotide sequences comprising restriction fragment length polymorphisms coding polypeptide with antiproliferative, antiviral and antiparasitic effects
07/22/2004US20040142404 Designing cyclic peptide which modulates tyrosine kinase activity and can be used as potential treatment for asthma, eczema, food allergies, cancer, inflammatory bowel and autoimmune diseases; enzyme inhibitors
07/22/2004US20040142395 Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
07/22/2004US20040142394 Method for diagnosing a tumor in a patient determining the concentration of PIBF
07/22/2004US20040142354 used to diagnose and/or treat a wide variety of liver and other disorders (cancer) and tracing hepatocyte lineage; genetic engineering
07/22/2004US20040142349 kit for detecting a risk of cancer, coronary or cerebrovascular disease, hypertension, type 2 diabetes, dementia, joint arthrosis, cataract, or sensitivity to organophosphorus compounds
07/22/2004US20040142342 Antibodies to non-functional P2X7 receptor diagnosis and treatment of cancers and other conditions
07/22/2004US20040142317 Use of amino acid transporter atbo,+ as a delivery system for drugs and prodrugs
07/22/2004US20040142047 Korean acanthopanax senticosus extract, protein extract, crude protein-polysaccharide which were extracted from korean acanthopanax senticosus, and immunoregulating compositions comprising the same and use thereof
07/22/2004US20040142000 Immune activator
07/22/2004US20040141992 derived from the same antigen as the substance eliciting the allergic reaction; contains an epitope different from that evoking the allergic reaction, yet does not elicit the allergic reaction
07/22/2004US20040141991 novel prostatic acid phosphatase and corresponding coding region derived from mouse; immunizing a subject with a xenogeneic polypeptide antigen, either alone, as part of a viral antigen construct, or as part of a pulsed dendritic cell preparation.
07/22/2004US20040141982 Use of genetically engineered antibodies to treat multiple myeloma
07/22/2004US20040141981 administering biological conjugates comprising chlorotoxin sensitive cytoplasmic proteins, used for the screening and prophylaxis of cancer
07/22/2004US20040141979 isolation and production of cancerous disease modifying antibodies (CDMAB) and to the use of these CDMAB in therapeutic and diagnostic processes; anticancer agents
07/22/2004US20040141966 Inhibition of leukocyte adhesion
07/22/2004US20040141958 cytotoxic T-cell mediated killing of disease cells that express a weakly immunogenic or non-immunogenic cell-associated polypeptide antigen in an animal by administering a cytotoxic T-cell epitope and a T-helper lymphocyte
07/22/2004US20040141918 Nucleotide and deduced amino acid sequences of tumor gene Int6
07/22/2004US20040141917 Antibodies to truncated VEGF-D and uses thereof
07/22/2004US20040141915 Cancerous disease modifying antibodies
07/22/2004US20040141914 Cancerous disease modifying antibodies
07/22/2004US20040141913 Cancerous disease modifying antibodies
07/22/2004US20040141912 Administering medicinally-useful agent which is phospholipid scramblase (PLS)-dependent transported compound to cells, thereby causing selective transport of agent into cells
07/22/2004DE202004003714U1 New phenyl maleic anhydride and maleimide derivatives used for lowering blood pressure, increasing high-density lipoprotein or as central cholinergic agonists, hepatoprotective, antiinflammatory agents and antitumor agents
07/22/2004CA2514477A1 Novel factor viia inhibiting compounds
07/22/2004CA2512553A1 Metastin derivatives and their use
07/22/2004CA2511817A1 Novel compositions and methods in cancer
07/22/2004CA2510050A1 The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
07/22/2004CA2509758A1 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
07/22/2004CA2509213A1 2-oxopyridin-3-yl thia (di) azole derivates for use in the treatment of cell proliferation and apoptosis related diseases
07/22/2004CA2503043A1 Compositions and methods for the diagnosis and treatment of tumor
07/21/2004EP1439229A2 Oncogene, recombinant protein derived therefrom, and uses thereof